Drugs / isovaleramide
isovaleramide
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00172094 | Dec 2003 → Jun 2004 | migraine disorder | Shire | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | isovaleramide | “NPS 1776, isovaleramide, is a neutral aliphatic amide.” NCT00172094 ↗ |
| Known as | NFS-1776 | ChEMBL registry synonym — accepted as the source's own label CHEMBL171066 ↗ |
| Known as | NPS 1776 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00172094 ↗ |
| Known as | NSC-402555 | ChEMBL registry synonym — accepted as the source's own label CHEMBL171066 ↗ |
| Modality | Small molecule | “NPS 1776, isovaleramide, is a neutral aliphatic amide.” NCT00172094 ↗ |
| Route | Oral | “a single oral dose of NPS 1776” NCT00172094 ↗ |